Cancer Care Companion for Pediatric Cancer

BA
Overseen ByBryan A Sisk, MD, MSCI
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a tool called the Cancer Care Companion, designed to help parents of children with cancer communicate more easily with their healthcare team. The goal is to determine if this tool is useful, appropriate, and practical for families dealing with a recent cancer diagnosis. Parents with a child diagnosed with cancer within the last four weeks and receiving treatment at St. Louis Children's Hospital can participate if they have internet access and can use the hospital's online portal. The trial aims to make managing a child's cancer care more manageable for parents. As an unphased trial, it offers parents the opportunity to contribute to research that could enhance communication and support for families facing similar challenges.

What prior data suggests that the Cancer Care Companion is safe for use in pediatric cancer care?

Research shows that the Cancer Care Companion, an electronic tool, helps parents of children with cancer communicate more effectively. As a communication tool rather than a medicine or physical treatment, its primary concern is usability and helpfulness, not traditional safety.

The tool seeks to enhance information sharing between parents and healthcare providers. Since it doesn't alter the body, there are no reports of physical side effects. The emphasis is on user experience—whether it is useful and easy to navigate. Research suggests it could aid families in managing communication during challenging times.12345

Why are researchers excited about this trial?

The Cancer Care Companion is unique because it aims to enhance the overall treatment journey for children with cancer through comprehensive support rather than focusing on the cancer itself. Unlike traditional cancer treatments like chemotherapy or radiation, which directly target cancer cells, the Cancer Care Companion provides emotional, educational, and logistical support to patients and their families. Researchers are excited about this program because it has the potential to improve quality of life and reduce stress for both patients and caregivers, offering a holistic approach to cancer care that current medical treatments do not address.

What evidence suggests that the Cancer Care Companion is effective for pediatric cancer care?

Research has shown that the Cancer Care Companion is an electronic tool designed to help parents communicate better when their child has cancer. Although direct proof of its impact on cancer treatment is not yet available, the tool aims to simplify managing and coordinating care, which is crucial for families dealing with cancer treatment. This trial will evaluate the effectiveness of the Cancer Care Companion program for all participants, as it lacks a control or comparison group. The tool could also benefit other serious childhood illnesses by organizing information and support. With more than 85% of children with cancer surviving at least five years, tools like this might significantly enhance the care experience. While specific data on its impact is still being gathered, the goal is to make care easier to understand and manage for families.12678

Who Is on the Research Team?

BA

Bryan A Sisk, MD, MSCI

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

This trial is for English-speaking parents or legal guardians of children recently diagnosed with cancer, who are receiving treatment at St. Louis Children's Hospital. Participants must have internet access and agree to use the Epic MyChart proxy portal.

Inclusion Criteria

I can speak and read English.
I have internet access via a computer or smartphone.
I agree to use Epic MyChart for my child's health information.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants use the Cancer Care Companion tool for 3 months

12 weeks
Ongoing access to the tool

Post-intervention Assessment

Participants complete a semi-structured interview and survey to assess the tool's acceptability, appropriateness, and feasibility

Immediately post-intervention

Follow-up

Participants are monitored for perceptions of tool usability and other secondary outcomes

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Cancer Care Companion

Trial Overview

The study is testing the Cancer Care Companion tool integrated into an electronic health record system to see if it's acceptable, appropriate, and feasible for communication about pediatric cancer care.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: All ParticipantsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Citations

Study Details | NCT07278778 | Cancer Care Companion

This study engages parents of children with cancer to use an electronic health record (EHR)-based communication tool, called the Cancer Care ...

Cancer Care Companion

Findings from this study could serve as a model communication tool for long-term cancer survivors or other serious pediatric illnesses. These findings will also ...

Progress in Pediatric Cancer Treatment

Advances in the treatment of pediatric cancers are reflected in the greater than 85 percent 5-year relative survival rates for all cancers combined among ...

Translating the science of care and cure for children with ...

The past 50 years have seen great progress for children with cancer, and yet, this progress has been largely unreached for most children.

THE CHILDHOOD CANCER CARE PLAN:

With increasing rates of survivorship (over 85% of children with a cancer diagnosis will survive), a multidisciplinary network of care providers support ...

Childhood Cancer

85% of children with cancer now survive 5 years or more. Overall, this is a huge improvement since the mid-1970s, when the 5-year survival rate was only about ...

Late Effects of Treatment for Childhood Cancer (PDQ®) - NCI

High-quality data is needed to establish the occurrence of and risk profiles for late cancer treatment–related toxicity.

New Research Links Some Pediatric Cancers to ...

The first study, published in December of 2023, links childhood leukemia, the most common of childhood cancers, with prenatal exposure to a ...